Is it time to commence newborn screening for congenital adrenal hyperplasia in Australia?

Medical Journal of Australia

Volumn 195, Issue 5, 2011, Pages 260-262

  Wu, Joyce Y ^a   Sudeep, ^b   Cowley, David M ^a   Harris, Mark ^b   Mcgown, Ivan N ^a   Cotterill, Andrew M ^b  

^a MATER HOSPITAL   (Australia)

^b MATER CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 21 MONOOXYGENASE;

ARTICLE; AUSTRALIA; CASE REPORT; CONGENITAL ADRENAL HYPERPLASIA; CYP21A2 GENE; DISEASE SEVERITY; ECHOGRAPHY; GENE; GENETIC SCREENING; HEART ARREST; HUMAN; INCIDENCE; INFANT; MALE; MECONIUM; NEWBORN SCREENING; PREVALENCE; STEROID 21 MONOOXYGENASE DEFICIENCY;

ADRENAL HYPERPLASIA, CONGENITAL; AUSTRALIA; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC TESTING; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INFANT, NEWBORN; MALE; NEONATAL SCREENING; PHENOTYPE; QUALITY ASSURANCE, HEALTH CARE; SENSITIVITY AND SPECIFICITY; STEROID 21-HYDROXYLASE;

EID: 80052468909     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja11.10284     Document Type: Article

References (25)

1. Riepe FG, Sippell WG. Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Rev Endocr Metab Disord 2007; 8: 349-363.
2. Ghayee HK, Auchus RJ. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Disord 2007; 8: 289-300.
3. Gleeson HK, Wiley V, Wilcken B, et al. Two-year pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. J Paediatr Child Health 2008; 44: 554-559.
4. Gozzi TG, Harris NP, McGown IN, et al. Autopsy diagnosis of 21-hydroxylase deficiency CAH in a case of apparent SIDS. Pediatr Dev Pathol 2005; 8: 397-401.
5. Van der Kamp HJ, Noordam K, Elvers B, et al. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics 2001; 108: 1320-1324.
6. White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 2009; 5: 490-498.
7. Therrell BL. Congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30: 15-30.
8. Watson MS, Mann MY, Lloyd-Puryear MA, et al. Newborn screening: toward a uniform screening panel and system - executive summary. Genet Med 2006; 8: 1S-11S.
9. Dietzen DJ, Rinaldo P, Whitley RJ, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry: executive summary. Clin Chem 2009; 55: 1615-1626.
10. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 4133-4160.
11. Brameld K. Congenital adrenal hyperplasia - the Australian perspective. Perth: Office of Population Health Genomics, Department of Health, Government of Western Australia, 2006. http://www.genomics.health.wa.gov.au/publications/docs/Congenital_Adrenal_Hyperplasia.pdf (accessed Aug 2011).
12. Brameld K. Framework for adding new tests for conditions within the Newborn Screening Protocol. Perth: Office of Population Health Genomics,Department of Health, Government of Western Australia, 2006. http://www.genomics.health.wa.gov.au/publications/docs/Newborn_Screening_Framework.pdf (accessed Aug 2011).
13. Human Genetics Society of Australasia, Royal Australasian College of Physicians. Newborn blood spot screening [policy statement]. Sydney: RACP, 2004. http://69.72.135.23/website/wp-content/uploads/2009/12/2004-P01.pdf (accessed Dec 2010).
14. Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics 2006; 117: S287-S295.
15. Yoo BK, Grosse SD. The cost effectiveness of screening newborns for congenital adrenal hyperplasia. Public Health Genomics 2009; 12: 67-72.
16. Thil'en A, Nordenström A, Hagenfeldt L, et al. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics 1998; 101 (4): e11.
17. Brosnan CA, Brosnan P, Therrell BL, et al. A comparative cost analysis of newborn screening for classic congenital adrenal hyperplasia in Texas. Public Health Rep 1998; 113: 170-178.
18. Speiser PW. Prenatal and neonatal diagnosis and treatment of congenital adrenal hyperplasia. Horm Res 2007; 68: 90-92.
19. Grosse S, Vliet GV. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res 2007; 67: 284-291.
20. van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol 2004; 151: U71-U75.
21. Brosnan PG, Brosnan CA, Kemp SF, et al. Effect of newborn screening for newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 1999; 153: 1272-1278.
22. Balsamo A, Cacciari E, Piazzi S, et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 1996; 98: 362-367.
23. Janzen N, Peter M, Sander S, et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2007; 92: 2581-2589.
24. De Jesús VR, Simms DA, Schiffer J, et al. Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening. Clin Chim Acta 2010; 411: 1684-1687.
25. Screening Matters. Newsletter of the National Screening Unit. 2006; Mar. http://www.nsu.govt.nz/files/NSU/issue_6.pdf (accessed Jul 2011).